The level of private-sector workers with job-based health care fell faster before Obamacare launched, but 11 million uninsured got covered afterward.» Read More
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.
Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.
Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.
Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders, and sickle cell anemia.
Brent Saunders, Actavis CEO, discusses the deal environment, the process of acquiring Allergan and the good that comes from activist investors.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
More and more Americans are "covered," but fewer and fewer Americans will actually be able to get health care, says Jake Novak. Here's why.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.
A flu shot that lasts 10 years could be a reality soon, a top hospital executive told CNBC, along with "real steps" toward a cancer vaccine.
Twenty-six children have died from the flu this season, and the rate of hospitalization among the elderly is rising, the CDC says.
Fitness club operators shouldn't look at wearables as a threat, but an opportunity, said Equinox Fitness CEO Harvey Spevak.
Ask venture capitalists in Silicon Valley about which industry they're most excited to revolutionize, and odds are high that they'll say health care.
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
Get the best of CNBC in your inbox